Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Verve Therapeutics, Inc. - Common Stock (NQ:VERV)

11.13 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Verve Therapeutics, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
Tesla, Coinbase Global And 41 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Intelligent Living Application Group Inc. (NASDAQ: ILAG) shares jumped 90.2% to $4.2792 after declining 11% on Friday. The company reported closing of $20.24 million initial public offering. 
Via Benzinga
News headline image
The Next CRISPR Is Here: How Verve Plans To Rival Amgen, Regeneron In Cholesterol ↗
This could offer an improvement over CRISPR, which requires cutting DNA. 
Via Investor's Business Daily
News headline image
Verve Therapeutics Amends Gene Editing Pact With Beam Therapeutics ↗
Verve Therapeutics Inc (NASDAQ: VERV) entered into an amended and restated collaboration and license Agreement with Beam Therapeutics Inc (NASDAQ: 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
On Tuesday, 951 companies hit new 52-week lows. 
Via Benzinga
News headline image
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
38 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Incannex Healthcare Limited (NASDAQ: IXHL) shares jumped 131.6% to $53.10 after jumping 54% on Monday. Incannex Healthcare recently completed a preliminary analysis of... 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
On Monday, 721 companies achieved new lows for the year. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 18, 2022 ↗
Upgrades Roth Capital upgraded the previous rating for Denbury Inc (NYSE:DEN) from Neutral to Buy. For the third quarter, Denbury had an EPS of $0.74, compared to year-ago... 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
On Thursday, 236 companies hit new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
On Tuesday, 242 companies hit new 52-week lows. Noteworthy Mentions In Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week low was... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Gainers Zogenix (NASDAQ:ZGNX) shares moved upwards by 67.2% to $26.15 during Wednesday's regular session. As of 12:30 EST, Zogenix's stock is trading at a volume... 
Via Benzinga
News headline image
68 Biggest Movers From Yesterday ↗
Gainers Sonim Technologies, Inc. (NASDAQ: SONM) shares jumped 103.3% to settle at $1.22 on Tuesday after the company announced its XP8 smartphone has integrated with the Walkie... 
Via Benzinga
News headline image
3 Synthetic Biology Stocks In Focus With Strong Potential ↗
Here we discuss three stocks engaged in the field of scientific biology that investors must follow, as they have the potential to generate wealth going forward. 
Via Talk Markets
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
During Tuesday's session, 454 stocks hit new 52-week lows. Intriguing Points From Today's 52-Week Lows: Taiwan Semiconductor (NYSE:TSM) was the largest company by... 
Via Benzinga
News headline image
Meme Stock Breakdown ↗
There have been plenty of market happenings and themes in 2021 but perhaps one of the more intriguing ones was the recurring bouts of meme stock mania. 
Via Talk Markets
News headline image
The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus MorphoSys COO To Leave To Pursue Other Opportunities MorphoSys AG (NASDAQ:... 
Via Benzinga
News headline image
Barron's Latest Picks And Pans: Alleghany, Blade Air Mobility, Gene Therapy Picks And More ↗
This weekend's Barron's cover story examines the bubbles in cryptocurrency, meme stocks and non-fungible tokens. Other featured articles discuss the stocks powering 2021... 
Via Benzinga
News headline image
Why Verve Therapeutics Is Up More Than 16% This Week ↗
The biotech stock rose nearly $7 a share from Monday through Thursday. 
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Gainers OptimizeRx (NASDAQ:OPRX) stock increased by 12.12% to $84.05 during Thursday's pre-market session. The company's market cap stands at $1.4 billion.... 
Via Benzinga
News headline image
Verve Therapeutics' Gene-Editing Therapy Shows Encouraging Preclinical Action In Cardiovascular Disease ↗
Verve Therapeutics Inc (NASDAQ: VERV) has reported new preclinical data from 36 non-human primates (NHPs) with its lead candidate, VERVE-101. VERVE-101 is a... 
Via Benzinga
News headline image
48 Biggest Movers From Friday ↗
Gainers Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) shares jumped 135.4% to settle at $5.32 on Friday. The stock possibly traded higher following favorable data results by... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 24, 2021 ↗
Upgrades Berenberg upgraded the previous rating for Tenable Holdings Inc (NASDAQ: 
Via Benzinga
News headline image
The Week Ahead In Biotech: Adcom Test Awaits FibroGen, Data Readouts, IPOs In The Mix ↗
Biopharma stocks closed the holiday-shortened week lower amid a lack of any significant news flow. On the drug approval front, Provention Bio, Inc. (NASDAQ: PRVB) faced a setback... 
Via Benzinga
News headline image
72 Biggest Movers From Yesterday ↗
Gainers aTyr Pharma, Inc. (NASDAQ: LIFE) jumped 67% to settle at $9.15 on Monday as the company announced positive results from its Phase 1b/2a trial evaluating its lead... 
Via Benzinga
News headline image
The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 7) Adial Pharmaceuticals, Inc... 
Via Benzinga
News headline image
The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 12, 2021 ↗
Upgrades According to Macquarie, the prior rating for 2U Inc (NASDAQ: 
Via Benzinga
News headline image
58 Biggest Movers From Yesterday ↗
Gainers The Glimpse Group, Inc. (NASDAQ: VRAR) shares jumped 152.3% to settle at $17.66 on Thursday after the company priced its IPO at $7 per share. Pop Culture Group Co., Ltd (... 
Via Benzinga
Topics Initial Public Offering
News headline image
The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 30) Ambrx Biopharma Inc. (NYSE... 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.